Glass House Brands (GLAS) Non-Current Assets (2020 - 2026)
Glass House Brands (GLAS) posted quarterly Non-Current Assets of $251.0 million for Q1 2026, up 3.27% year-over-year from $243.0 million in Q1 2025, and up 3370.7% quarter-over-quarter from $7.2 million in Q4 2025.
Glass House Brands (GLAS) Non-Current Assets (2020 - 2026) Analysis & Trends
Glass House Brands (GLAS) has reported Non-Current Assets for 7 consecutive years, with $251.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Non-Current Assets rose 3.27% year-over-year to $251.0 million; the TTM figure through Mar 2026 stood at $987.6 million (down 0.74% YoY), while the FY2025 annual figure was $7.2 million, up 66.91% from the prior year.
- Non-Current Assets climbed to $251.0 million in Q1 2026 per GLAS's latest filing, from $7.2 million in the prior quarter.
- Across five years, Non-Current Assets topped out at $304.3 million in Q3 2022 and bottomed at $2.4 million in Q4 2022.
- Historically, Non-Current Assets has averaged $200.1 million across 5 years, with a median of $248.1 million in 2025.
- Annual changes were most pronounced in 2022 — Non-Current Assets soared 430.62% — and 2024, when it slipped 12.96%.
- Glass House Brands' Non-Current Assets stood at $2.4 million in 2022, then surged by 78.8% to $4.2 million in 2023, then rose by 2.78% to $4.3 million in 2024, then surged by 66.91% to $7.2 million in 2025, then soared by 3370.7% to $251.0 million in 2026.
- Business Quant data shows GLAS's Non-Current Assets at $251.0 million in Q1 2026, $7.2 million in Q4 2025, and $245.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | 37.96 Bn |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 26.10 Bn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 8.72 Bn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 78.51 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 3.74 Bn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | 24.99 Bn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 3.72 Bn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 9.76 Bn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | 2.96 Bn |
| 10 | Glass House Brands | 837.25 Mn | 818.69 Mn | 15.77 Mn | 242.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 251.00 Mn |
| Dec 31, 2025 | 7.23 Mn |
| Sep 30, 2025 | 245.48 Mn |
| Jun 30, 2025 | 248.06 Mn |
| Mar 31, 2025 | 243.04 Mn |
| Dec 31, 2024 | 4.33 Mn |
| Sep 30, 2024 | 245.40 Mn |
| Jun 30, 2024 | 253.38 Mn |
| Mar 31, 2024 | 253.17 Mn |
| Dec 31, 2023 | 4.22 Mn |
| Sep 30, 2023 | 281.93 Mn |
| Jun 30, 2023 | 277.30 Mn |
| Mar 31, 2023 | 286.84 Mn |
| Dec 31, 2022 | 2.36 Mn |
| Sep 30, 2022 | 304.29 Mn |
| Jun 30, 2022 | 262.50 Mn |
| Mar 31, 2022 | 230.59 Mn |
| Dec 31, 2021 | -62.91 Mn |
| Sep 30, 2021 | 208.06 Mn |
| Jun 30, 2021 | 49.47 Mn |